Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PYGM | P11217 | 1/20 | 0.30 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542184 | 0.88 | ADAMTS7 (0.35) | TDP1ADAMTS7 | |
| SCHEMBL542745 | 0.84 | TDP1 (0.36) | TDP1ADAMTS7 | |
| SCHEMBL15974011 | 0.84 | GAA (0.36) | TDP1ADAMTS7 | |
| SCHEMBL15974332 | 0.82 | GAA (0.36) | TDP1 | |
| SCHEMBL8958230 | 0.82 | GAA (0.36) | TDP1 | |
| SCHEMBL15974003 | 0.78 | ABCB1 (0.34) | ADAMTS7 | |
| SCHEMBL15973968 | 0.75 | RAB9A (0.32) | TDP1 | |
| SCHEMBL6212012 | 0.70 | TDP1 (0.33) | TDP1 | |
| SCHEMBL1100894 | 0.70 | TDP1 (0.33) | TDP1 | |
| SCHEMBL8686431 | 0.69 | APP (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-11306068-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20200308139-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2020-10-01 | — | — | US | disclosed |
| US-10710975-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | GABRA1 633/4885GABRG2 951/4885GABRB3 1390/4885 |
| US-11306068-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | GABRA1 633/4885GABRG2 951/4885GABRB3 1390/4885 |
| US-10710975-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | GABRA1 633/4885GABRG2 951/4885GABRB3 1390/4885 |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | GABRA1 633/4885GABRG2 951/4885GABRB3 1390/4885 |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | GABRA1 633/4885GABRG2 951/4885GABRB3 1390/4885 |
| US-20200308139-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | GABRA1 633/4885GABRG2 951/4885GABRB3 1390/4885 |
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | GABRA1 633/4885GABRG2 951/4885GABRB3 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.